The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHeiq Regulatory News (HEIQ)

Share Price Information for Heiq (HEIQ)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.20
Bid: 8.90
Ask: 9.20
Change: -0.23 (-2.48%)
Spread: 0.30 (3.371%)
Open: 9.00
High: 9.20
Low: 9.00
Prev. Close: 9.28
HEIQ Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition of Chem-Tex Laboratories, Inc

2 Dec 2022 07:00

RNS Number : 3428I
HeiQ PLC
02 December 2022
 

2 December 2022

 

HeiQ Plc

("HeiQ" or "the Company")

 

Acquisition of Chem-Tex Laboratories, Inc

 

HeiQ Plc (LSE: HEIQ), an established global brand in materials and textile innovation which operates in high-growth markets, is pleased to announce the acquisition of the land and property of Chem-Tex Laboratories, Inc. ("Chem-Tex") in North Carolina, USA ("the Acquisition") for a total consideration of US$2.5 million. US$550,000 will be paid in cash and US$1.95 million in HeiQ Plc shares. The Acquisition will strengthen the Company's footprint in the USA, which is a key market for HeiQ.

 

Since May 2017, HeiQ's US subsidiary, HeiQ ChemTex has leased Chem-Tex's real estate property in Concord, North Carolina to develop and manufacture specialty chemicals for the functional flooring, textile, and industrial chemicals industries. HeiQ has now made a strategic decision to assume ownership of the land and property in order to safeguard past and future investments into its operations site. HeiQ foresees further expansion of the location over the coming years, serving mainly its global textile, functional flooring and industrial chemicals business.  

This Acquisition is expected to improve HeiQ's operating margin in 2023 and beyond and will also enable HeiQ to focus its future manufacturing investments in the USA, which have proven to be less exposed to energy price increases and critical base chemical raw materials availability challenges experienced in Europe in the recent years.

 

The sellers of Chem-Tex are three trusts, the beneficiaries of which are related to a minority shareholding of HeiQ Plc.

Recently joined HeiQ Chemtex Inc. (USA) CEO, Mike Abbott (former Hanes Inc. CTO) said:  

"We are excited to announce the acquisition of Chem-Tex's land and property, which is expected to improve operating margin for 2023 and beyond and also enable further expansion of HeiQ's current footprint in the USA market, that remains resilient in the current volatile macroeconomic environment."

 

Issue of Equity and Total Voting Rights 

 

The Company will issue 2,176,884 new ordinary shares ("Consideration Shares") to the sellers of Chem-Tex, at a price of £0.744 per share, which is the average 5 day closing price prior to signing in order to part satisfy the consideration due. Applications will be made for the Consideration Shares to be admitted to the standard segment of the Official List, and to trading on the London Stock Exchange's Main Market ("Admission").

 

It is expected that Admission will become effective, and that dealings in the new Ordinary Shares are expected to commence, at 08.00 a.m. on 8 December 2022.

 

Following Admission, the total number of Ordinary Shares in issue will be 136,734,308 and the total number of voting rights will therefore be 136,734,308. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

This announcement contains inside information.

 

For further information, please contact:

HeiQ Plc

Carlo Centonze (CEO)

+41 56 250 68 50

Cenkos Securities plc (Joint Broker)

Stephen Keys / Callum Davidson

+44 (0) 207 397 8900

SEC Newgate (Media Enquiries)

Elisabeth Cowell / Axaule Shukanayeva / Molly Gretton

+44 (0) 20 3757 6882

HeiQ@secnewgate.co.uk

 

About HeiQ

HeiQ is focused on improving the lives of billions of people world-wide by innovating the materials people use every day. HeiQ has strong IP which is at the forefront of global technology in the $10 billion antimicrobial fabrics market, $24 billion textile chemicals market, the $50 billion probiotics market and the $150 billion man-made fibers market. It has also moved into the medical device, healthcare and hygiene coatings markets, to help make hospitals and healthcare environments more hygienic. HeiQ aims to deliver growth for its shareholders through a combination of increased sales of its core products and by entering additional lucrative markets through disruptive innovations and M&A.

HeiQ has created some of the most effective, durable and high-performance technologies in the market today, which cool, warm, dry, repel, purify, and destroy viruses. Since 2005, HeiQ has developed over 200 technologies in partnership with 300 major brands and it has a significant R&D pipeline containing over 50 projects. The Company has won multiple awards and gained a strong reputation for the ESG & sustainable downstream effect of its innovations. HeiQ is the only company to have won the Swiss Technology award twice. It has also won the Swiss Environmental award with an innovation that saves energy and water consumption during the textile manufacturing process.

Led by an experienced leadership team, HeiQ researches new solutions for partners, delivers scaled up manufacturing from its sites across the world and helps partners market the product to end consumers - aiming for lab to consumer in months.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQEAXAFEDLAFFA
12
Date   Source Headline
22nd Apr 20247:00 amRNSHeiQ Synbio Secures Ecolab Contract Win
16th Apr 20242:17 pmRNSHolding(s) in Company
28th Mar 20247:00 amRNSUnaudited Interim Results
18th Mar 202412:41 pmRNSHolding(s) in Company
15th Mar 20247:00 amRNSHolding(s) in Company
14th Mar 20241:23 pmRNSCompletion of Fundraising, PDMR & Audit Update
13th Mar 20242:26 pmRNSResult of General Meeting
12th Mar 20247:00 amRNSBoard Changes
23rd Feb 20247:00 amRNSResult of Retail Offer
16th Feb 20247:00 amRNSResult of Placing
15th Feb 20245:49 pmRNSRetail Offer
15th Feb 20245:46 pmRNSAcquisition, Fundraising, Trading Update & GM
6th Dec 20232:46 pmRNSAgreed Changes to Concert Party
4th Dec 20237:00 amRNSDirector/PDMR Dealing
1st Dec 20233:04 pmRNSResult of General Meeting
30th Nov 20237:06 amRNSStatement Confirming Settlement
27th Nov 20237:00 amRNSBoard Appointment
8th Nov 20237:00 amRNSNotice of General Meeting
3rd Nov 20239:14 amRNSHolding(s) in Company
3rd Nov 20237:05 amRNSHolding(s) in Company
31st Oct 20237:43 amRNSFiling of Annual Report & Restoration of Trading
31st Oct 20237:30 amRNSRestoration - HEIQ PLC
30th Oct 20237:01 amRNSInterim Results
30th Oct 20237:00 amRNSResults for year ended 31 December 2022
23rd Oct 20237:00 amRNSNotice of Results and Audit Update
29th Sep 20237:00 amRNSAccounts Update
6th Jul 20237:00 amRNSMAS Holdings invests in HeiQ AeoniQ
29th Jun 20232:16 pmRNSResult of AGM
29th Jun 20237:00 amRNSAGM Statement
6th Jun 20237:00 amRNSNotice of AGM
2nd May 20237:44 amRNSTemporary Suspension of Trading in Ordinary Shares
27th Apr 20233:55 pmRNSTemporary Suspension
13th Jan 20232:09 pmRNSUpdate re. admission of Consideration Shares
12th Jan 20237:00 amRNSCompletion of Acquisition
10th Jan 20237:00 amRNSDirector / PDMR Dealing
6th Jan 20237:00 amRNSDirector / PDMR Dealing
5th Jan 20237:03 amRNSDirector/PDMR Shareholding
4th Jan 20237:00 amRNSTrading Update and Acquisition
14th Dec 20227:00 amRNSIncreased interest in HeiQ Chrisal to 71%
2nd Dec 20227:00 amRNSAcquisition of Chem-Tex Laboratories, Inc
7th Nov 20227:00 amRNSChange of Auditor
10th Oct 20227:00 amRNSFiles Breach of Exclusive Agreement Complaint
13th Sep 20227:00 amRNSInterim Results
30th Aug 20227:00 amRNSNotice of H1 2022 Results and Presentation
8th Aug 202210:33 amRNSIssue of Equity and Total Voting Rights
29th Jun 202211:06 amRNSResult of AGM
14th Jun 20227:00 amRNSCommercial progress of HeiQ’s Hygiene technologies
18th May 20227:00 amRNSNotice of AGM
12th May 20227:00 amRNSPayment of Earnout Consideration
28th Apr 20227:00 amRNSResults for the year ended 31 December 2021
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.